These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15598031)

  • 1. Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.
    Ritter CA; Bianco R; Dugger T; Forbes J; Qu S; Rinehart C; King W; Arteaga CL
    Int J Clin Pharmacol Ther; 2004 Nov; 42(11):642-3. PubMed ID: 15598031
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting alternative pathways in HER2-positive breast cancer.
    Rastogi P
    Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
    [No Abstract]   [Full Text] [Related]  

  • 3. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
    Slamon DJ
    Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
    [No Abstract]   [Full Text] [Related]  

  • 5. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 6. Ten years of HER2-directed therapy: still questions after all these years.
    Krop IE; Winer EP
    Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
    [No Abstract]   [Full Text] [Related]  

  • 7. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 8. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
    Flaherty KT; Brose MS
    Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Targeting ErbB receptors in breast cancer].
    Fumoleau P; Campone M; Coudert B; Mayer F; Favier L; Ferrant E
    Bull Cancer; 2007; 94(7 Suppl):F147-70. PubMed ID: 17964992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Nielsen DL; Andersson M
    Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 13. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
    Normanno N; Bianco C; De Luca A; Maiello MR; Salomon DS
    Endocr Relat Cancer; 2003 Mar; 10(1):1-21. PubMed ID: 12653668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
    Magné N; Milano G
    Bull Cancer; 2004 Dec; 91 Suppl 4():S257-60. PubMed ID: 15899618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeted therapies in breast cancer].
    Jerusalem G; Collignon J; Rorive A; Lifrange E; André C; Martin M; Maweja S; Coucke P
    Rev Med Liege; 2011; 66(5-6):379-84. PubMed ID: 21826980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual blockade of HER2 - twice as good or twice as toxic?
    Fralick M; Hilton JF; Bouganim N; Clemons M; Amir E
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):593-603. PubMed ID: 22748560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 as a cancer stem-cell target.
    Roesler R; Cornelio DB; Abujamra AL; Schwartsmann G
    Lancet Oncol; 2010 Mar; 11(3):225-6. PubMed ID: 20202610
    [No Abstract]   [Full Text] [Related]  

  • 18. [New treatment approaches in breast cancer].
    Spirig C; Thürlimann B; Huober J
    Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
    [No Abstract]   [Full Text] [Related]  

  • 20. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.